Zoll Medical’s Zenix monitor/defibrillator is now approved under the European Union’s Medical Device Regulation 2017/745, commonly referred to as EU MDR.
The Zenix monitor/defibrillator received premarket approval (PMA) from the US FDA in October 2025.
Built from years of feedback from customers, Zenix combines design and functionality to automate workflows for ease-of-use, according to the company. The device features a large, durable touchscreen and its on-the-fly customization allows healthcare professionals to make real-time adjustments.
Equipped with Zoll’s Real BVM Help and exclusive Real CPR Help technology, Zenix gives healthcare providers real-time clinical feedback to improve ventilation quality and deliver high-quality CPR.1
The advanced technology of Zenix empowers EMS teams and hospital clinicians to make informed, confident decisions and ensure they are delivering exceptional patient care, every time, according to the company.
“Whether you are a hospital clinician or an EMS professional, the Zoll Zenix monitor/defibrillator is designed to work the way you work,” said Elijah White, President of Zoll Acute Care Technology. “Zenix is our most advanced monitor/defibrillator, and yet it’s incredibly easy to use—virtually all functions of the device are accessible with three screen-touches or less. Along with the X Series, R Series and Zoll M2, Zenix extends Zoll’s leadership in professional monitors/defibrillators with unique features and intuitive design.”
